Immunotherapy

CellPoint and Lonza Enter Strategic Collaboration to Deliver CAR-T Cells to Patients at Point-of-Care

Retrieved on: 
Wednesday, June 23, 2021

CellPoint and Lonza will utilize Lonza's CocoonPlatformin combination with CellPoint's online xCellit Platform for workflow managementto manufacture cell therapies at the point-of-care.

Key Points: 
  • CellPoint and Lonza will utilize Lonza's CocoonPlatformin combination with CellPoint's online xCellit Platform for workflow managementto manufacture cell therapies at the point-of-care.
  • Tol Trimborn, Chief Executive Officer of CellPoint, said: "CellPoint's T-cell therapies have enormous potential for treating various cancers.
  • Eytan Abraham, Head of Lonza Personalized Medicine, commented: "We look forward to collaborating with CellPoint to enable and accelerate bringing novel cancer immunotherapies to the clinic and patients.
  • CellPoint is a Dutch (EU) company founded to provide affordable and readily available CAR-T therapies for all patients in need.

Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®

Retrieved on: 
Wednesday, June 23, 2021

LAWRENCEVILLE, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announces that its new wholly owned subsidiary, Celsion GmbH, will manage all current and future investigator-sponsored development of ThermoDox, the Companys proprietary heat-activated liposomal encapsulation of doxorubicin.

Key Points: 
  • LAWRENCEVILLE, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announces that its new wholly owned subsidiary, Celsion GmbH, will manage all current and future investigator-sponsored development of ThermoDox, the Companys proprietary heat-activated liposomal encapsulation of doxorubicin.
  • A clinical project at the National Institutes of Health to evaluate ThermoDox plus the chemotherapy drug mitomycin in bladder cancer.
  • Celsion GmbHs long-term objective is to seek partnerships that will maximize the potential of ThermoDox, ultimately providing value to the parent company.
  • Celsion also has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies.

eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix®

Retrieved on: 
Wednesday, June 23, 2021

This new license stems from the collaboration between the VUB and eTheRNA focussed on directed activation of dendritic cells and leverages research performed at the Laboratory for Molecular and Cellular Therapy ( LMCT ) of the VUB.

Key Points: 
  • This new license stems from the collaboration between the VUB and eTheRNA focussed on directed activation of dendritic cells and leverages research performed at the Laboratory for Molecular and Cellular Therapy ( LMCT ) of the VUB.
  • "We have already demonstrated that TriMix has a benign safety profile and promotes high mRNA expression levels," comments Steven Powell, CEO, eTheRNA.
  • "TetraMix will now be integrated into our programs to engineer new generation mRNA immunotherapies offering even greater efficacy and immunogenicity."
  • Technologies such as mRNA, lentiviral vectors, and single domain antibodies (better known as nanobodies) are employed for these purposes.

eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix®

Retrieved on: 
Wednesday, June 23, 2021

This new license stems from the collaboration between the VUB and eTheRNA focussed on directed activation of dendritic cells and leverages research performed at the Laboratory for Molecular and Cellular Therapy ( LMCT ) of the VUB.

Key Points: 
  • This new license stems from the collaboration between the VUB and eTheRNA focussed on directed activation of dendritic cells and leverages research performed at the Laboratory for Molecular and Cellular Therapy ( LMCT ) of the VUB.
  • "We have already demonstrated that TriMix has a benign safety profile and promotes high mRNA expression levels," comments Steven Powell, CEO, eTheRNA.
  • "TetraMix will now be integrated into our programs to engineer new generation mRNA immunotherapies offering even greater efficacy and immunogenicity."
  • Technologies such as mRNA, lentiviral vectors, and single domain antibodies (better known as nanobodies) are employed for these purposes.

NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410

Retrieved on: 
Monday, June 21, 2021

The publication titled, "Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking LAIR-collagen interaction," details the preclinical development and characterization of NC410.

Key Points: 
  • The publication titled, "Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking LAIR-collagen interaction," details the preclinical development and characterization of NC410.
  • It also highlights preclinical data from a series of murine xenograft efficacy studies demonstrating anti-tumor activity and the promotion of T cell expansion and infiltration in the TME by NC410.
  • In preclinical studies, NC410 blocked the negative effects of LAIR-1 and promoted T cell function and myeloid cell activity.
  • NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

Virion Therapeutics Announces Presentation of Preclinical Data of VRON-0200, a Chronic Hepatitis B Virus (HBV) Therapeutic Vaccine, at the International Liver Congress (ILC)

Retrieved on: 
Monday, June 21, 2021

These results were only observed if Virions novel checkpoint inhibitor, gD, was present in the vaccine.This oral platform presentation was selected by the EASL-ILC Organizing Committee as a Best of ILC for highlight at the meeting.

Key Points: 
  • These results were only observed if Virions novel checkpoint inhibitor, gD, was present in the vaccine.This oral platform presentation was selected by the EASL-ILC Organizing Committee as a Best of ILC for highlight at the meeting.
  • Data to be presented at the EASL-ILC meeting:
    The above presentation will be available on June 25, 2021, via the EASL-ILC meeting website, https://easl.eu/event/the-international-liver-congress-2021 .
  • Virion Therapeutics, LLC, is a science driven company developing innovative immune-based treatments for virally associated cancers and chronic viral infections utilizing the first genetically encoded checkpoint inhibitor given via vaccination.
  • Our novel T cell-based immunotherapies induce potent, diverse and sustained T cell-mediated immune responses, allowing us to target common diseases with unmet medical needs.

Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company

Retrieved on: 
Tuesday, June 22, 2021

Blackstone (NYSE: BX) announced today that funds managed by Blackstone Life Sciences have committed $250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company, along with Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Cellex Cell Professionals GmbH (Cellex), the parent company of GEMoaB GmbH (GEMoaB), a clinical-stage cell therapy company.

Key Points: 
  • Blackstone (NYSE: BX) announced today that funds managed by Blackstone Life Sciences have committed $250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company, along with Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Cellex Cell Professionals GmbH (Cellex), the parent company of GEMoaB GmbH (GEMoaB), a clinical-stage cell therapy company.
  • Intellia Therapeutics is a clinical stage, leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology.
  • Cellex Cell Professionals GmbH holds the clinical-stage biopharmaceutical company GEMoaB, which is focused on the development of next-generation immunotherapies and cell therapies for hard-to-treat cancers.
  • Blackstone Life Sciences, Intellia and Cellex (and certain related entities) will each have equal ownership of the new company.

SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerging Diseases

Retrieved on: 
Tuesday, June 22, 2021

The execution of this merger agreement caps 18 months of tremendous progress at SAB, said Eddie Sullivan, PhD, co-founder and chief executive officer of SAB Biotherapeutics.

Key Points: 
  • The execution of this merger agreement caps 18 months of tremendous progress at SAB, said Eddie Sullivan, PhD, co-founder and chief executive officer of SAB Biotherapeutics.
  • The unique attributes of our DiversitAb platform power our diversified strategy that includes rapid response, development of our own novel therapeutics, and a variety of pharma collaborations.
  • SAB Biotherapeutics is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies based on its human polyclonal antibodies.
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies based on its human polyclonal antibodies.

Unicorn Hunters Presents to Investors Worldwide a Biopharmaceutical Company Fighting Food-Related Allergies

Retrieved on: 
Monday, June 21, 2021

"People with food allergies are desperate for options in this growing epidemic," said Michael Nelson, Chief Executive Officer and Co-founder, Intrommune Therapeutics.

Key Points: 
  • "People with food allergies are desperate for options in this growing epidemic," said Michael Nelson, Chief Executive Officer and Co-founder, Intrommune Therapeutics.
  • Intrommune's immunotherapy toothpaste, known as INT301 is in Phase 1 clinical development for patients with peanut-related allergies.
  • New episodes of Unicorn Hunters air every other Monday at 10AM EDT on UnicornHunters.comwith parallel distribution on LinkedIn Broadcast, Facebook Video, YouTube and Vimeo.
  • The show provides investors with transparent access to select pre-IPO investment opportunities, and boosts innovation by financing emerging growth companies.

IMV Announces Annual and Special Meeting of Shareholders Voting Results

Retrieved on: 
Friday, June 18, 2021

Please refer to the Circular available on SEDAR at www.sedar.com for more information on the business transacted at the Meeting.

Key Points: 
  • Please refer to the Circular available on SEDAR at www.sedar.com for more information on the business transacted at the Meeting.
  • A report on voting results will also be filed on SEDAR.
  • IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.
  • IMV is pioneering a new class of cancer immunotherapies and vaccines against infectious diseases based on the Companys proprietary drug delivery platform, DPX.